['prostatic neoplasms']
['radium-223 dichloride (xofigo, bay88-8223)', 'matching placebo (normal saline)', 'abiraterone', 'prednisone/prednisolone']

        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate

          -  Male subjects of age ≥ 18 years

          -  Prostate cancer progression documented by prostate specific antigen (PSA) according to
             the Prostate Cancer Working Group 2 (PCWG2) criteria or radiological progression
             according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1

          -  Two or more bone metastases on bone scan within 4 weeks prior to randomization with no
             lung, liver, other visceral and/or brain metastasis

          -  Asymptomatic or mildly symptomatic prostate cancer

          -  Subjects who received combined androgen blockade with an anti-androgen must have shown
             PSA progression after discontinuing the anti-androgen prior to enrollment

          -  Maintenance of medical castration or surgical castration with testosterone less than
             50 ng/dL (1.7nmol/L)

          -  Eastern Cooperative Oncology Group performance status (ECOG PS) score 0 or 1

        Exclusion Criteria:

          -  Prior cytotoxic chemotherapy for the treatment of CRPC, including taxanes,
             mitoxantrone and estramustine

          -  Any chronic medical condition requiring a higher dose of corticosteroid than 5 mg
             prednisone/prednisolone twice daily

          -  Pathological finding consistent with small cell carcinoma of the prostate

          -  History of visceral metastasis, or presence of visceral metastasis detected by
             screening imaging examinations

          -  History of or known brain metastasis

          -  Malignant lymphadenopathy exceeding 3 cm in short-axis diameter

          -  Blood transfusion or erythropoietin stimulating agents prior 4 weeks of screening and
             during the whole screening period before randomization

          -  Imminent spinal cord compression based on clinical findings and/or magnetic resonance
             imaging (MRI). Subjects with history of spinal cord compression should have completely
             recovered

          -  Use of opiate analgesics for cancer-related pain, including codeine and
             dextropropoxyphene, currently or anytime during the 4- week period prior to
             randomization.
      